Nanoscope Therapeutics Wins ‘2022 Biotech Innovation Award’
Bedford, TX, January 12, 2022 – Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic gene therapies for treatment of retinal degenerative diseases, today announced that it has been named winner in the “Biotech Innovation” category at the D CEO and Dallas Innovates third annual 2022 Innovation Awards, which honors disruptors and trailblazers contributing to the North Texas Hi-Tech corridor.
In accepting the award, Nanoscope Co-Founder and CEO Sulagna Bhattacharya stated, “A big thanks to the hard-working and talented team at Nanoscope. I am also thankful to Dallas Innovates and D CEO magazine for their support of the Biotech industry and for recognizing companies like ours, focused on finding cures for previously-untreatable diseases. This award highlights the potential of our gene therapy to address unmet medical needs for millions of patients with retinal diseases around the world”.
Nanoscope’s proprietary Multi-Characteristic Opsin (MCO) gene therapy platform is in late-stage clinical development for restoration of vision in patients blinded by retinal degenerative diseases, such as retinitis pigmentosa (RP), regardless of genetic mutations and type of retinal degenerative disease.
“Biotech Innovation requires passion and perseverance. When we started 12 years back, gene therapy held promise and hope. Now, in this exciting era of gene therapy, we are on the cusp of bringing restorative therapy for blindness caused by retinal degenerative diseases,” said Samarendra Mohanty, Co-Founder and President of Nanoscope.
The company’s lead product, MCO-010, is in a Phase 2b multicenter, randomized, double-masked, sham controlled clinical trial in the US for treatment of RP (NCT04945772), and is expanding into macular degeneration with another Phase 2 trial on Stargardt disease. In a Phase 1/2a trial of MCO-010, all 11 RP patients experienced restoration of vision to a level sufficient to resume activities of daily living. Nanoscope has received orphan drug designation from the U.S. FDA for RP and Stargardt disease.
About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing optogenetic therapies for giving sight to the millions of blind individuals suffering from retinal degenerative diseases, for which no cure exists. The company’s pipeline includes optogenetics based retinal regeneration therapy for patients with retinitis pigmentosa, Stargardt disease, and other IRDs as well as macular degenerations. Nanoscope is also advancing a proprietary non-viral laser gene delivery platform for targeted MCO therapy of geographic atrophies. For more information visit: https://nanostherapeutics.com/
Opus Biotech Communications